{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA-mutated+Solid+Tumor",
    "query": {
      "condition": "BRCA-mutated Solid Tumor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:08:15.401Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06395519",
      "title": "A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Breast Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Epithelial Ovarian Cancer",
        "BRCA2 Mutation",
        "ER+ Breast Cancer",
        "Castrate Resistant Prostate Cancer",
        "BRCA1 Mutation",
        "BRCA Mutation",
        "Endometrial Cancer",
        "Colorectal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "ETX-19477",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "858 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2024-05-13",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06395519"
    },
    {
      "nct_id": "NCT04673448",
      "title": "Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "BRCA-Associated Malignant Neoplasm",
        "BRCA Hereditary Ovarian Carcinoma",
        "Metastatic BRCA Hereditary Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Unresectable Breast Carcinoma",
        "Unresectable Fallopian Tube Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Ovarian Carcinoma",
        "Unresectable Pancreatic Carcinoma",
        "Unresectable Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dostarlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-10-18",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673448"
    },
    {
      "nct_id": "NCT02950064",
      "title": "A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Ovarian Neoplasms",
        "Breast Neoplasms",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BTP-114",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Placon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2016-09",
      "completion_date": "2020-08",
      "has_results": false,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 8,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02950064"
    },
    {
      "nct_id": "NCT05252390",
      "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Cancer of Ovary",
        "Cancer of the Ovary",
        "Ovary Neoplasm",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Pancreas Neoplasm",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration Resistant Prostatic Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Triple-negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Breast Tumor"
      ],
      "interventions": [
        {
          "name": "NUV-868",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2022-03-29",
      "completion_date": "2024-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05252390"
    },
    {
      "nct_id": "NCT06065059",
      "title": "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Pancreas Cancer",
        "Prostate Cancer",
        "BRCA1 Mutation",
        "BRCA-Mutated Ovarian Carcinoma",
        "BRCA-Associated Breast Carcinoma",
        "HRD Positive Advanced Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TNG348",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tango Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-12-08",
      "completion_date": "2024-05-22",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06065059"
    },
    {
      "nct_id": "NCT01078662",
      "title": "Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian",
        "Breast",
        "Prostate",
        "Pancreatic",
        "Advanced Tumours"
      ],
      "interventions": [
        {
          "name": "olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 298,
      "start_date": "2010-02-21",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 2,
      "location_summary": "West Hollywood, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01078662"
    },
    {
      "nct_id": "NCT00892736",
      "title": "Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Basal-Like Breast Carcinoma",
        "BRCA1 Mutation Carrier",
        "BRCA2 Mutation Carrier",
        "Breast Carcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Hereditary Breast and Ovarian Cancer Syndrome",
        "Ovarian Carcinoma",
        "Pancreatic Carcinoma",
        "Progesterone Receptor Negative",
        "Prostate Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Solid Neoplasm",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2009-04-20",
      "completion_date": "2017-05-19",
      "has_results": false,
      "last_update_posted_date": "2018-06-29",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00892736"
    },
    {
      "nct_id": "NCT02358200",
      "title": "Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Metastatic Breast Cancer",
        "BRCA-mutated Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BMN-673",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pamela Munster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2015-02-23",
      "completion_date": "2019-01-08",
      "has_results": false,
      "last_update_posted_date": "2020-01-10",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02358200"
    },
    {
      "nct_id": "NCT04672460",
      "title": "A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Solid Tumors",
        "Ovarian Cancer",
        "Breast Cancer",
        "Prostate Cancer",
        "NSCLC",
        "Pancreatic Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TALZENNA capsule",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib soft gel capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 73,
      "start_date": "2020-12-21",
      "completion_date": "2022-07-22",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 23,
      "location_summary": "Encinitas, California • Los Angeles, California • San Marcos, California + 12 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04672460"
    },
    {
      "nct_id": "NCT01482715",
      "title": "A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Advanced Solid Tumor With Evidence of Germline or Somatic BRCA"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2011-11",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-07-23T23:08:15.401Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482715"
    }
  ]
}